Brain-Computer Interface Company Synchron Raises $200M
Synchron, a New York-based company specializing in non-surgical brain-computer interface (BCI) technology, announced it has secured $200 million in a Series D funding round. This capital injection aims to fast-track the commercialization of its first-generation Stentrode BCI platform and support development of a next-generation interface.
Funding Details and Investors
- The new financing brings Synchron’s total funding to $345 million.
- Double Point Ventures led the round.
- Existing investors include ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New participants are the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
The Stentrode Platform
Synchron’s Stentrode is the first endovascular brain-computer interface designed to convert brain activity into digital commands without requiring open-brain surgery.
The Stentrode is “placed via a non-surgical catheter procedure” and interfaces with the motor cortex through blood vessels, “recording and transmitting neural signals wirelessly to enable hands-free control of digital devices.”
Technology Significance
This innovative approach allows for brain-device communication with a minimally invasive technique, providing a breakthrough in neurotechnology by avoiding the risks associated with traditional brain surgery.
Synchron’s progress reflects a significant leap toward practical brain-computer interfaces with broad applications in medicine and technology.
Author’s summary: Synchron raised $200 million to accelerate the rollout of its groundbreaking Stentrode brain interface—which translates neural signals wirelessly via a minimally invasive catheter-based method.